Their findings, published in the Journal of Clinical Investigation, found that over-expression of the growth protein Cripto-1 makes lung cancer cells resistant to the drug erlotinib (Tarceva®). Experiments in cell lines and in animals demonstrated that blocking Cripto-1 signaling transduction restored sensitivity to the drug, one of a number of EGFR inhibitors used in non-small cell lung carcinoma and other cancers.
The drug they used is a Src inhibitor, because Cripto-1 activates the oncogenic tyrosine-protein kinase Src. And although the specific drug they used is no longer available, at least one similar Src inhibitor has been approved by the U.S. Food and Drug Administration for treatment of chronic myelogenous leukemia.
“This is a welcome finding because Cripto-1 belongs to a family of proteins that can be targeted by drugs that have already been developed,” says the study’s senior investigator, Giuseppe Giaccone, MD, PhD, associate director for clinical research at Georgetown Lombardi.
He said that Georgetown Lombardi is preparing a clinical trial to see if what they observed in the lab will work in patients. The trial will test a combination of erlotinib and a Src inhibitor (AZD0424) in patients with non-small cell lung cancer. They will select patients whose cancer cells harbor a mutation in their EGFR because these patients are most sensitive to erlotinib.
“There has been very little investigation when a person never responds to an EGFR inhibitor — most research has been done on acquired resistance that occurs after the drug has shown some benefit,” he says.
“Most patients using erlotinib exhibit either intrinsic or acquired resistance, so we frankly don’t cure anyone with the drug, although we can extend lifespan,” Giaccone says. “So if we can understand what is limiting the activity of the drug up front, I believe treatment of patients can be vastly improved.”
The study was supported by the National Cancer Institute intramural fund and Georgetown Lombardi.
The authors report no personal financial interests related to the study.
Co-authors include: Kang-Seo Park, Deepa Subramaniam, and Yisong Wang from Georgetown Lombardi; Mark Raffeld, Yong Wha Moon, Liqiang Xi, Caterina Blanco, Trung Phaam, Liam C. Lee, Ji Luo, and David S. Salomon from the National Cancer Institute; Tetsuya Mitsudomi and Isamu Okamoto from Kinki University in Japan; Yasushi Yatabe from Aichi Cancer Center Hospital in Japan; Tony Mok from the University of Hong Kong, and Rafael Rosell from Catalan Institute of Oncology in Spain.
About Georgetown Lombardi Comprehensive Cancer Center
Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and MedStar Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Georgetown Lombardi is one of only 41 comprehensive cancer centers in the nation, as designated by the National Cancer Institute (grant #P30 CA051008), and the only one in the Washington, DC area. For more information, go to http://lombardi.georgetown.edu.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC’s mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis – or “care of the whole person.” The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical and Translational Science Award from the National Institutes of Health.